ELI LILLY AND COMPANY Available-for-sale Securities, Gross Unrealized Gain
ELI LILLY AND COMPANY (LLY) reported Available-for-sale Securities, Gross Unrealized Gain of $250.70 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-04-30.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains · last filed 2015-04-30
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized gain for the quarter ending 2015-03-31 was $250.70M, a 14.70% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized gain for the quarter ending 2014-12-31 was $18.30M, a 84.22% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized gain for the quarter ending 2014-09-30 was -$53.20M, a 168.65% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized gain for the quarter ending 2014-06-30 was -$87.10M.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized gain for fiscal 2012 was $140.50M.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized gain for fiscal 2010 was $262.60M, a 18.08% increase from fiscal 2009.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized gain for fiscal 2009 was $222.40M.
| Period end | Available-for-sale Securities, Gross Unrealized Gain 3 month | Available-for-sale Securities, Gross Unrealized Gain 6 month | Available-for-sale Securities, Gross Unrealized Gain 9 month | Available-for-sale Securities, Gross Unrealized Gain 12 month |
|---|---|---|---|---|
| 2015-03-31 | $250.70M 10-Q · filed 2015-04-30 | $269.00M derived: sum of 2 quarters · filed 2015-04-30 | $215.80M derived: sum of 3 quarters · filed 2015-04-30 | $128.70M derived: sum of 4 quarters · filed 2015-04-30 |
| 2014-12-31 | $18.30M derived: 10-Q 12 month − 10-Q 9 month · filed 2015-04-30 | -$34.90M derived: sum of 2 quarters · filed 2015-04-30 | -$122.00M derived: sum of 3 quarters · filed 2015-04-30 | $171.90M 10-Q · filed 2015-04-30 |
| 2014-09-30 | -$53.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | -$140.30M derived: sum of 2 quarters · filed 2014-10-29 | $153.60M 10-Q · filed 2014-10-29 | $269.60M derived: sum of 4 quarters · filed 2014-10-29 |
| 2014-06-30 | -$87.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-28 | $206.80M 10-Q · filed 2014-07-28 | $322.80M derived: sum of 3 quarters · filed 2014-10-29 | $400.30M derived: sum of 4 quarters · filed 2014-10-29 |
| 2014-03-31 | $293.90M 10-Q · filed 2014-04-28 | $409.90M derived: sum of 2 quarters · filed 2014-10-29 | $487.40M derived: sum of 3 quarters · filed 2014-10-29 | |
| 2013-12-31 | $116.00M derived: 10-Q 12 month − 10-Q 9 month · filed 2014-10-29 | $193.50M derived: sum of 2 quarters · filed 2014-10-29 | $375.60M 10-Q · filed 2014-10-29 | |
| 2013-09-30 | $77.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $259.60M 10-Q · filed 2013-10-30 | ||
| 2013-06-30 | $182.10M 10-Q · filed 2013-07-26 | |||
| 2012-12-31 | $140.50M 10-K · filed 2014-02-19 | |||
| 2010-12-31 | $262.60M 10-K · filed 2011-02-22 | |||
| 2010-09-30 | $230.40M 10-Q · filed 2010-10-29 | $407.60M derived: sum of 2 quarters · filed 2010-10-29 | ||
| 2010-06-30 | $177.20M 10-Q/A · filed 2010-08-02 | |||
| 2009-12-31 | $222.40M 10-Q · filed 2010-10-29 | $222.40M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |